PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Elizabeth K., Matulonis, Ursula A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465003/
https://www.ncbi.nlm.nih.gov/pubmed/32722408
http://dx.doi.org/10.3390/cancers12082054
_version_ 1783577491610271744
author Lee, Elizabeth K.
Matulonis, Ursula A.
author_facet Lee, Elizabeth K.
Matulonis, Ursula A.
author_sort Lee, Elizabeth K.
collection PubMed
description The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi.
format Online
Article
Text
id pubmed-7465003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74650032020-09-04 PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies Lee, Elizabeth K. Matulonis, Ursula A. Cancers (Basel) Review The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi. MDPI 2020-07-25 /pmc/articles/PMC7465003/ /pubmed/32722408 http://dx.doi.org/10.3390/cancers12082054 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lee, Elizabeth K.
Matulonis, Ursula A.
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title_full PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title_fullStr PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title_full_unstemmed PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title_short PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
title_sort parp inhibitor resistance mechanisms and implications for post-progression combination therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465003/
https://www.ncbi.nlm.nih.gov/pubmed/32722408
http://dx.doi.org/10.3390/cancers12082054
work_keys_str_mv AT leeelizabethk parpinhibitorresistancemechanismsandimplicationsforpostprogressioncombinationtherapies
AT matulonisursulaa parpinhibitorresistancemechanismsandimplicationsforpostprogressioncombinationtherapies

Ejemplares similares